Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Entera Bio (NASDAQ:ENTX) announced its earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports.

Entera Bio Stock Down 2.6 %

Shares of ENTX stock traded down $0.05 during trading on Friday, reaching $1.75. The company’s stock had a trading volume of 55,218 shares, compared to its average volume of 111,862. Entera Bio has a one year low of $1.41 and a one year high of $3.35. The business has a fifty day moving average price of $2.15 and a 200-day moving average price of $2.02. The company has a market cap of $62.62 million, a price-to-earnings ratio of -6.73 and a beta of 1.62.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research report on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.